Psoriasis Clinical Trial

A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients

Summary

To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Study participants must have biopsy-proven psoriasis with 3 distinct psoriatic lesions. (Biopsy-proven Reiter's syndrome patients with 3 distinct cutaneous lesions may be included.) Documented HIV antibody (by federally licensed ELISA test) positive patients.

Prior Medication:

Allowed:

Zidovudine (AZT).

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Presence of any active opportunistic infection.
Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
Known hypersensitivity to zidovudine (AZT).
Impaired renal function.
Significant hepatic dysfunction.

Concurrent Medication:

Excluded:

- Topical steroid, anthralin, or tar preparations. Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy. Psoriatic treatment such as systemic agents or topical steroids (emollients used distal to the control lesions and antipruritic shampoos are admissible).

Patients with the following are excluded:

Presence of any active opportunistic infection.
Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma) such as central nervous system (CNS) lymphoma.
Known hypersensitivity to zidovudine (AZT).
Impaired renal function.
Significant hepatic dysfunction.

Prior Medication:

Excluded:

Other antiretroviral agents (e.g., suramin, ribavirin, HPA-23, dideoxycytidine).
Excluded within 2 weeks of study entry:
Topical steroid, anthralin, or tar preparations.
Any other experimental therapy drugs which cause significant bone marrow suppression such as antifolates or pyrimethamine.
Cytolytic chemotherapy.
Drugs which cause significant nephrotoxicity or hepatotoxicity.
Rifampin or rifampin derivatives.
Excluded within 4 weeks of study entry:
Etretinate, methotrexate, or psoralen ultraviolet A (PUVA) therapy.
Excluded within 8 weeks of study entry:
Immunomodulating agents, including steroids, interferon, Isoprinosine, and interleukin 2.

Study is for people with:

Psoriasis

Study ID:

NCT00002286

Recruitment Status:

Completed

Sponsor:

Glaxo Wellcome

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Glaxo Wellcome Inc
Research Triangle Park North Carolina, 27709, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Study ID:

NCT00002286

Recruitment Status:

Completed

Sponsor:


Glaxo Wellcome

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider